Literature DB >> 18724234

Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus.

José M Morales1, Josep M Grinyó, Josep M Campistol, Javier García-Martínez, Manuel Arias, Javier Paul, Ana Sánchez-Fructuoso, Mercé Brunet, Enrique Granados, Jorge A Munoz-Robles.   

Abstract

Results at 1 year of a pilot randomized trial with 87 kidney graft recipients, comparing the maintenance treatment with sirolimus, tacrolimus and steroids (group I) versus tacrolimus withdrawal since the third month onward, followed by maintenance with SRL and steroids (group II) have shown that early elimination of tacrolimus may result in improved renal function and blood pressure control. At 2 years, 26 and 25 patients in groups I and II, respectively, were analyzed in an on-therapy and an ITT analysis. In the on-therapy analysis, group II showed lower serum creatinine (1.3+/-0.2 vs. 1.6+/-0.6 mg/dL) and lower diastolic blood pressure (74+/-9 vs. 80+/-11 mm Hg). No acute rejections occurred during the second year of follow-up. In more than 90% of patients, proteinuria was less than 1 g/d, and in 50% it was negative. In the ITT analysis, differences were found only in diastolic blood pressure (80+/-10 vs. 74+/-8 mm Hg in groups I and II respectively, P=0.009). Tacrolimus withdrawal from a combination of sirolimus and tacrolimus, in selected patients, may be observed at 2 years by an improvement in renal function and blood pressure without a higher incidence of proteinuria.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18724234     DOI: 10.1097/TP.0b013e3181821c25

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

Review 1.  Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.

Authors:  Krishna M Karpe; Girish S Talaulikar; Giles D Walters
Journal:  Cochrane Database Syst Rev       Date:  2017-07-21

2.  Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.

Authors:  Deirdre Hahn; Elisabeth M Hodson; Lorraine A Hamiwka; Vincent Ws Lee; Jeremy R Chapman; Jonathan C Craig; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2019-12-16

3.  Alloimmunity to Class 2 Human Leucocyte Antigens May Reduce HIV-1 Acquisition - A Nested Case-Control Study in HIV-1 Serodiscordant Couples.

Authors:  Melinda S Suchard; Neil Martinson; Susan Malfeld; Debbie de Assis Rosa; Romel D Mackelprang; Jairam Lingappa; Xuanlin Hou; Helen Rees; Sinead Delany-Moretlwe; Hadassa Goldfein; Heena Ranchod; David Coetzee; Kennedy Otwombe; Lynn Morris; Caroline T Tiemessen; Dana M Savulescu
Journal:  Front Immunol       Date:  2022-03-24       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.